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Introduction
Normal vasculature is quiescent in healthy adults with
each endothelial cell dividing once every 10 years; active
angiogenesis is required only for wound healing,
endometrial proliferation, postlactational mammary gland
involution, and pregnancy. In contrast, tissue remodeling
and angiogenesis are crucial for the growth and
metastasis of breast cancer, providing an attractive
therapeutic target [1]. The central importance of
angiogenesis and our understanding of how new blood
vessels are formed have led to novel therapies designed
to interrupt this process (see http://www.angiogenesis.org
or http://cancernet.nci.nih.gov for a detailed list of agents
in development). Although the number of ongoing phase I
and II trials has grown rapidly, few have been reported in
the peer-reviewed literature. To date only one phase III trial
in breast cancer has been completed.
Antiangiogenic agents may be conceptually categorized
as follows: endothelial toxins, which specifically target
endothelial antigens; growth factor/receptor antagonists,
which thwart signaling of proangiogenic growth factors;
protease inhibitors, which interfere with the action of
proteases that are critical for invasion; and natural
inhibitors, which stimulate or mimic endogenous inhibitors
of angiogenesis. In addition, several chemotherapeutic
agents routinely employed in breast cancer treatment have
true antiangiogenic activity. Clinical experience with
representative agents in each category is reviewed.
Endothelial toxins
Disruption of endothelial cell chemotaxis and migration
interferes with angiogenesis. The integrins, particularly αvβ3,
provide critical attachment between the migrating
endothelial cell and the extracellular matrix [2]; αvβ3 also
localizes matrix metalloproteinase (MMP)-2 to the
membrane of endothelial cells in the leading podosomes of
new vessels, providing carefully targeted matrix destruction
[3]. Vitaxin™ (Medimmune, Gaithersburg, MD, USA), a
humanized monoclonal antibody recognizing αvβ3 (also
known as the vitronectin receptor), inhibits endothelial
proliferation in vitro and tumor growth in vivo [4]. In phase I
trials Vitaxin™ was well tolerated but had limited activity
[5,6]. Imaging tumor vasculature with 99mTc Vitaxin™ was
unsuccessful in one pilot study including at least one patient
with αvβ3 positive melanoma [7]. Phase II trials are ongoing.
Commentary
Recent translational research: antiangiogenic therapy for breast
cancer – where do we stand?
Kathy D Miller
Indiana University, Indianapolis, Indiana, USA
Correpsonding author: Kathy D Miller (e-mail: kathmill@iupui.edu)
Published: 18 March 2004
Breast Cancer Res 2004, 6:128-132 (DOI 10.1186/bcr782)
© 2004 BioMed Central Ltd
Abstract
The central importance of angiogenesis and our understanding of how new blood vessels are formed
have led to the development of novel antiangiogenic therapies. Although the number of agents in
development has grown exponentially, only one phase III trial in breast cancer has been completed. In
that study the addition of bevacizumab to capecitabine did not extend the progression-free survival of
patients with refractory disease as compared with capecitabine monotherapy. Early enthusiasm for
antiangiogenic therapy must give way to clinical reality. Our challenge now is to exploit better the
activity of antiangiogenic agents seen in the early clinical studies.
Keywords: angiogenesis, breast cancer, matrix metalloproteinase inhibitor, vascular endothelial growth factor129
Available online http://breast-cancer-research.com/content/6/3/128
Growth factor antagonists
Angiogenesis requires stimulation of vascular endothelial
cells through the release of angiogenic peptides, of which
the vascular endothelial growth factor (VEGF) is the most
potent. VEGF is a highly conserved, homodimeric,
secreted, heparin-binding glycoprotein, the dominant
isoform of which has a molecular weight of about 45 kDa
[8]. The biologic effects of VEGF are mediated through
binding to one of three endothelial surface receptors –
VEGF-R1 (flt-1), VEGF-R2 (flk-1/kdr), and VEGF-R3;
binding to the coreceptor neurophilin enhances signaling
[9,10]. Although the VEGF receptors share considerable
overlap in ligand binding, downstream effector interaction
and biologic function, predominant actions have been
identified. VEGF-R1 promotes differentiation and vascular
maintenance [11]; VEGF-R2 induces endothelial cell
mitogenesis and vascular permeability [12]; and VEGF-R3
stimulates lymphangiogenesis [13,14].
Bevacizumab (Avastin™; Genentech, South San Francisco,
CA, USA), a humanized monoclonal antibody directed
against VEGF-A, inhibits growth of human tumors in animal
models [15]. A phase II study of bevacizumab monotherapy
conducted in 75 patients with previously treated metastatic
breast cancer [16] reported a 9.3% objective response
rate with 17% of patients responding or stable at
22 weeks; four patients continued therapy without
progression for over 12 months. Bevacizumab both alone
and in combination with chemotherapy was well tolerated,
with hypertension, proteinuria, thrombosis, and bleeding
being the most commonly reported toxicities [17,18].
A recently reported phase III trial randomly assigned 462
patients with anthracycline- and taxane-refractory disease
to receive capcitabine with or without bevacizumab; the
primary end-point was progression-free survival as assessed
by an independent review facility. As expected, bevacizumab
therapy induced hypertension, proteinuria, and minor
mucosal bleeding but these toxicities were rarely severe;
12% of patients in each group discontinued therapy
because of toxicity. Combination therapy significantly
increased the response rates whether designated by the
independent review facility (9.1% versus 19.8%;
P = 0.001) or the local investigators (19.1% versus 30.2%;
P = 0.006). Because many of the excess responses in the
combination group were relatively short-lived, progression
free survival was similar in both groups (4.17 versus 4.86
months; hazard ratio = 0.98) [19]. Analysis of primary
tumor samples for pathologic factors correlating with
response to bevacizumab is ongoing. Initial results were
limited by the small number of patients contributing
samples but did not clearly identify a subset more likely to
benefit [20]. A phase III trial (E2100) comparing paclitaxel,
administered weekly for 3 out of 4 weeks, without or without
bevacizumab in chemo-naïve patients with metastatic
breast cancer is ongoing.
Protease inhibitors
Degradation of the basement membrane and surrounding
stroma by the MMPs is crucial for direct tissue invasion
and angiogenesis. MMP inhibitors significantly curtail
primary breast tumor growth and establishment of
metastases in preclinical xenograft models but they fail to
shrink large, well established tumors [21]. Nonetheless,
previous MMP inhibitors were tested largely in patients
with metastatic disease. Whether administered as
monotherapy or in combination with cytotoxic agents, the
results were nearly uniform. MMP inhibitors had little
activity in advanced disease, leading to termination of
clinical development of several agents [22–26]. The most
successful clinical application of MMP inhibitors was
hypothesized to be in patients with micrometastatic
disease. However, two adjuvant pilot trials demonstrated
intolerable musculoskeletal toxicity [27,28], making
chronic administration of potentially therapeutic doses in
the adjuvant setting implausible. The critical question, that
regarding whether it is possible to separate inhibition of
MMPs important in cancer progression from those whose
inhibition produces joint toxicity, remains.
Endogenous antiangiogenics
A naturally occurring metabolite of estradiol, namely 2-
methoxyestradiol (2ME2), has a dual mechanism of action
[29,30]: it acts as an antiproliferative drug, exerting its
effect directly on the tumor cell compartment, and as an
antiangiogenic drug, acting on tumor vasculature. Recent
studies suggested that 2ME2 uses the extrinsic pathway
for induction of apoptosis. 2ME2 upregulates death
receptor 5 expression in vitro and in vivo, rendering cells
more sensitive to the death receptor 5 ligand, tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL).
Inhibition of death receptor signaling by a dominant-
negative Fas-associated death domain severely attenuates
the 2ME2-induced apoptosis [31].
The first phase I trial of 2ME2 was conducted in patients
with previously treated metastatic breast cancer [32].
2ME2 was administered orally once (200–1000 mg/day;
cohorts 1–5) or twice daily (200–800 mg every 12 hours;
cohorts 6–9). Maximum tolerated dose was not reached.
Metabolism was variable, with a half-life of approximately
10–12 hours. No objective responses were produced
although prolonged disease stabilization was achieved in
several patients. A second phase I study combined 2ME2
with docetaxel [33]. Treatment was well tolerated, with no
detectable pharmacokinetic interaction. An overall
response rate of 20% was reported; an additional 40% of
patients had stable disease. In both phase I trials
conversion to 2-methoxyestrone, an inactive metabolite,
was significant, with 2-methoxyestrone concentrations
generally 10-fold higher than 2ME2 levels. 2ME2 levels
were substantially below those required for activity based
on preclinical models. A new formulation with increased130
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bioavailability and activity in animal models is expected to
re-enter clinical trials in 2004.
Antiangiogenic chemotherapy
The intense interest in angiogenesis has also lead to a re-
examination of the activity of many established cytotoxic
agents. Several chemotherapeutic agents used routinely in
breast cancer treatment have known antiangiogenic
activity [34]. Maximal antiangiogenic activity typically
requires prolonged exposure to low drug concentrations,
exactly counter to maximum tolerated doses administered
when optimal tumor cell kill is the goal. A number of recent
reports confirm the importance of dose and schedule in
preclinical models. In most models, the combination of
low, frequent dose chemotherapy plus an agent that
specifically targets the endothelial cell compartment
controls tumor growth much more effectively than
cytotoxic therapy alone [35–39]. These studies suggest
that activated endothelial cells may be more sensitive, or
even selectively sensitive, to protracted low-dose
chemotherapy compared with other types of normal cells,
thus creating a potential therapeutic window. Such
selective sensitivity has been confirmed for several agents
[40]. The antiangiogenic effect reported with low dose
cyclophosphamide or microtubule agents may be due to
induction of thrombospondin-1, a potent and endothelial-
specific inhibitor of angiogenesis [41].
Thus far, few clinical trials have directly tested
antiangiogenic schedules of chemotherapy. Nonetheless,
the limited clinical evidence is intriguing. Remissions can
be induced, albeit infrequently, in patients resistant to
taxane therapy administered on an every 3-week basis by
administering lower doses weekly [42]. E1199, a recently
completed phase III adjuvant trial, compares paclitaxel
with docetaxel weekly versus every 3 weeks and will
determine the value of antiangiogenic taxane schedules.
The European Organization for Research and Treatment of
Cancer studied two CMF (cyclophosphamide, methotrexate,
and 5-fluorouracil) regimens [43]: a classic 28-day
regimen incorporating daily oral cyclophosphamide for
14 days and a modified intravenous schedule with bolus
cyclophosphamide every 3 weeks. Overall response rate
and survival clearly favored the classic regimen. Although
generally viewed as a test of dose intensity (the classic
regimen delivered higher total doses of both
cyclophosphamide and 5-fluoruracil), that study may also
be considered a test of an antiangiogenic versus bolus
schedule. Superiority of the classic regimen in the adjuvant
setting has also been suggested in a retrospective study of
two groups of patients treated at different institutions [44].
A phase II study of low dose methotrexate (2.5 mg twice
daily for 2 days each week) and cyclophosphamide
(50 mg/day) in patients with previously treated metastatic
breast cancer found an overall response rate of 19% (an
additional 13% of patients were stable for 6 months or
more). Serum VEGF levels decreased in all patients
remaining on therapy for at least 2 months but this did not
correlate with response [45]. Several ongoing trials in
both the metastatic and adjuvant setting are investigating
this regimen further.
Conclusion
Our challenge now is to exploit better the activity of
antiangiogenic agents seen in the early clinical studies.
Thus far, antiangiogenic agents have been employed as
general therapies given on a population basis, rather than
as targeted therapies given to patients with a specific
molecular phenotype. We must develop ways to select
those patients who are most likely to benefit from each
antiangiogenic agent. Perhaps even more importantly, the
best time to intervene with an antiangiogenic agent may
be earlier in the course of disease. Angiogenic pathways
become more numerous and redundant as breast cancer
progresses [46]. Given such redundancy, it is unlikely that
inhibition of a single factor or pathway would produce a
sustained clinical effect in patients with previously treated,
highly refractory disease. As such, future trials must focus
on patients with less advanced disease.
Early enthusiasm for antiangiogenic therapy, justified by
impressive preclinical data, has given way to clinical reality –
genes are not proteins are not cells are not tissues are not
organs are not mice are not patients. Although the early
rampant enthusiasm has been dampened, cautious optimism
rightly remains. It now seems certain that antiangiogenic
therapies will be integrated into routine clinical practice.
To believe otherwise would be to assume that
angiogenesis is both biologically crucial yet therapeutically
unimportant, which is an unlikely paradox.
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